Literature DB >> 18585670

The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers.

Trinh Ngoc Hai1, Sofia Friberg Hietala, Nguyen Van Huong, Michael Ashton.   

Abstract

The combination piperaquine and dihydroartemisinin is emerging as first line treatment of uncomplicated falciparum malaria in Southeast Asia. The aim of this study was to determine the influence of a standard Vietnamese meal on the single-dose pharmacokinetics of piperaquine when administered in combination with dihydroartemisinin, and to gain extended data on the terminal half-life of piperaquine in healthy Vietnamese volunteers. Subjects were randomly assigned to take a single oral dose of piperaquine phosphate (640 mg)+dihydroartemisinin (80 mg) together with a standardized Vietnamese meal (n=16) or to remain fasting for 4h following drug intake (n=16). Frequent blood sampling was conducted during 36 h, followed by weekly samples for 7 weeks. The pharmacokinetic parameters of piperaquine were determined by noncompartmental analysis. The median (80% central range) AUC(0-last) was 11.5 (6.9-17.3)h mg/L in fed and 13.9 (2.8-19.3)h mg/L in fasting subjects, indicating a considerable variability in exposure in both groups. The estimated overall oral clearance was 0.27 (0.12-1.49)L/(h kg), the volume of distribution during the terminal elimination phase was 230 (102-419)L/kg and estimated terminal half-life was 18 (5-93) days. This study did not demonstrate a significant impact of a standardized Vietnamese meal on the oral absorption of piperaquine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585670     DOI: 10.1016/j.actatropica.2008.05.013

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  22 in total

1.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Kevin T Batty; Kaye Kose; Susan Griffin; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin.

Authors:  Stephanie E Reuter; Allan M Evans; Sepehr Shakib; Yvonne Lungershausen; Barbara Francis; Giovanni Valentini; Antonella Bacchieri; David Ubben; Silvia Pace
Journal:  Clin Drug Investig       Date:  2015-09       Impact factor: 2.859

4.  Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Authors:  Jessica Manning; Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Mary So; Darapiseth Sea; Youry Se; Sok Somethy; Sut-Thang Phann; Soklyda Chann; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mashamon Mitprasat; Raveewan Siripokasupkul; Paktiya Teja-Isavadharm; Eugene Soh; Ans Timmermans; Charlotte Lanteri; Jaranit Kaewkungwal; Montida Auayporn; Douglas Tang; Char Meng Chour; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.

Authors:  Rada M Savic; Prasanna Jagannathan; Richard Kajubi; Liusheng Huang; Nan Zhang; Moses Were; Abel Kakuru; Mary K Muhindo; Norah Mwebaza; Erika Wallender; Tamara D Clark; Bishop Opira; Moses Kamya; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Francesca T Aweeka
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

7.  Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Authors:  Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh
Journal:  J Infect Dis       Date:  2013-02-27       Impact factor: 5.226

8.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

9.  Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.

Authors:  Quique Bassat; Modest Mulenga; Halidou Tinto; Patrice Piola; Steffen Borrmann; Clara Menéndez; Michael Nambozi; Innocent Valéa; Carolyn Nabasumba; Philip Sasi; Antonella Bacchieri; Marco Corsi; David Ubben; Ambrose Talisuna; Umberto D'Alessandro
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

10.  Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.

Authors:  D M Kiboi; B N Irungu; B Langat; S Wittlin; R Brun; J Chollet; O Abiodun; J K Nganga; V C S Nyambati; G M Rukunga; A Bell; A Nzila
Journal:  Exp Parasitol       Date:  2009-03-24       Impact factor: 2.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.